Lipid Nanoparticle Freeze-Drying for Room-Temperature Storage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preparing lipid nanoparticles for biologically active agents face challenges in scalability, reproducibility, stability, and storage, particularly for RNA-based formulations, which require deep-freeze temperatures and an uninterrupted cold chain, making them difficult to ship and store effectively.
Innovation Solution
A method involving the mixing of an organic lipid solution with an aqueous biologically active agent stream to form nascent lipid nanoparticles, followed by direct filling into primary packaging containers and subsequent freeze drying, conducted under aseptic conditions, to produce stable lyophilized compositions that can be easily reconstituted for use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If deep-freeze storage is used for RNA-based lipid nanoparticles, then biological activity is maintained, but storage and shipping logistics become difficult and costly
Solution Approach 1:
The patent changes the physical state parameter of the lipid nanoparticle composition from liquid to solid by incorporating specific excipients (sucrose, trehalose, mannitol, or xylose) that enable freeze-drying. This transformation allows the composition to be stored at room temperature while maintaining biological activity, eliminating the need for deep-freeze storage and improving logistics.
Solution Approach 2:
The patent introduces excipients (sucrose, trehalose, mannitol, or xylose) as intermediary substances that mediate between the lipid nanoparticle formulation and the storage conditions. These excipients protect the RNA and lipid nanoparticles during freeze-drying and storage, enabling stable room temperature storage while maintaining biological activity.
2Adaptability or versatility
If conventional mixing methods are used for preparing lipid nanoparticles, then formulation flexibility is maintained, but scalability and reproducibility become difficult
Solution Approach 1:
The patent replaces conventional mechanical mixing methods with a microfluidic mixing system. The microfluidic device provides controlled laminar flow and precise mixing through diffusion in a standardized geometry, enabling scalable and reproducible production while maintaining formulation flexibility through programmable flow rates and composition control.
Solution Approach 2:
The patent designs a universal microfluidic platform that can produce various lipid nanoparticle formulations by changing input compositions and flow parameters rather than requiring different mixing devices. This multi-functional approach enables both formulation flexibility and manufacturing precision through a single standardized system.
3Manufacturing precision
If microfluidic platforms are used for mixing, then mixing precision is improved, but manufacturing complexity and upscaling challenges increase
Solution Approach 1:
The patent segments the manufacturing process into distinct functional modules: separate reservoirs for each component, individual channels for each stream, and a standardized mixing chamber. This modular segmentation enables precise control of mixing while simplifying scaling through replication of modular units rather than redesign.
Solution Approach 2:
The patent achieves scaling by changing operational parameters (flow rates, channel dimensions) rather than fundamentally redesigning the mixing mechanism. The standardized microfluidic geometry allows parameter optimization for different production scales while maintaining mixing precision through diffusion-controlled laminar flow.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the production of stable, scalable, and reproducible lipid nanoparticle compositions that can be stored at room temperature, improving handling and shipping logistics while maintaining biological activity, and allows for efficient reconstitution into a ready-to-use form.
Implementation Method 1
mixing of an organic lipid solution with an aqueous biologically active agent stream to form nascent lipid nanoparticles
Implementation Method 2
subsequent freeze drying, conducted under aseptic conditions, to produce stable lyophilized compositions
Data Source
AI summary
The invention provides methods of preparing lipid nanoparticles with biologically active agents associated with and/or encapsulated within the lipid nanoparticles. The method comprises the steps of (a) providing a first stream of a first liquid composition comprising an organic solution of one or more lipids; (b) providing a second stream of a second liquid composition comprising an aqueous solution of the biologically active agent; (c) mixing the first stream and the second stream such as to form a third stream of a third liquid composition comprising nascent lipid nanoparticles; (d) filling the third liquid composition into primary packaging containers without prior removal or addition of a constituent from or to the third liquid composition; and (e) subjecting the primary packaging containers to freeze drying such as to obtain a lyophilised composition. Steps (a) to (e) are conducted under aseptic conditions.